

Brothers,

FYI.

Bill

---

**From:** kathy.schnakenberg@dot.gov [mailto:kathy.schnakenberg@dot.gov]  
**Sent:** Monday, February 12, 2007 12:33 PM  
**Subject:** FDA Warning

See the email below: Drug Advisory Warning that SEPTA's Medical Review Officer distributed regarding an FDA prescription package warning for Requip and Mirapex (used to treat restless leg syndrome):

**Richard A Press** <rpress@septa.org> wrote:  
From: "Richard A Press" <rpress@septa.org>  
To: <mro@mail.rochester.edu>  
Subject: Warning on Requip and Mirapex  
Date: Mon, 12 Feb 2007 10:38:36 -0500

MRO group, here's a notice I just sent around... FYI...

Drug Advisory: Warning about REQUIP and MIRAPEX

This is to advise all employees about a potential danger from using a highly-advertised medication for restless leg syndrome. The drug is called Requip, and another, similar drug is called Mirapex which has the same warning.

Safety-sensitive employees at SEPTA must not use these medications. Please consult your provider for possible alternative remedies.

Below is part of the bold-letter warning accompanying these drugs:

**Falling Asleep During Activities of Daily Living:** Patients treated with Requip or Mirapex have reported falling asleep while engaged in activities of daily living, including the operation of motor vehicles, which sometimes resulted in accidents. Although many of these patients reported somnolence while on Requip or Mirapex, some perceived that they had no warning signs such as excessive drowsiness, and believed that they were alert immediately prior to the event. Some of these events have been reported as late as 1 year after initiation of treatment.

Supervisors are asked to post a copy of this message.

Richard A. Press, MD, FACOEM  
Medical Director  
Southeastern Pennsylvania Transportation Authority  
1234 Market Street  
Philadelphia, PA 19107  
(215) 580-7749

Kathy Schnakenberg  
FRA Drug & Alcohol Program Specialist  
2920 Grand Avenue, KC, MO 64108  
Phone: 816-561-2714  
Cell: 202-262-4998  
Kathy.Schnakenberg@dot.gov